Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian cancer in patients who have exhausted standard therapies.
The company said a Phase 1 study of CTIM-76 is currently underway, with interim data expected in June 2026.
Shares of Context Therapeutics rose more than 3% in pre-market trading after closing at $2.65 on Wednesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.